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We have previously reported on the death effector
domain containing E8 gene product from equine herpes-
virus-2, designated FLICE inhibitory protein (v-FLIP),
and on its cellular homologue, c-FLIP, which inhibit the
activation of caspase-8 by death receptors. Here we re-
port on the structure and function of the E10 gene prod-
uct of equine herpesvirus-2, designated v-CARMEN, and
on its cellular homologue, c-CARMEN, which contain a
caspase-recruiting domain (CARD) motif. c-CARMEN is
highly homologous to the viral protein in its N-terminal
CARD motif but differs in its C-terminal extension. v-
CARMEN and c-CARMEN interact directly in a CARD-
dependent manner yet reveal different binding specific-
ities toward members of the tumor necrosis factor
receptor-associated factor (TRAF) family. v-CARMEN
binds to TRAF6 and weakly to TRAF3 and, upon overex-
pression, potently induces the c-Jun N-terminal kinase
(JNK), p38, and nuclear factor (NF)-kB transcriptional
pathways. c-CARMEN or truncated versions thereof do
not appear to induce JNK and NF-kB activation by
themselves, nor do they affect the JNK and NF-kB acti-
vating potential of v-CARMEN. Thus, in contrast to the
cellular homologue, v-CARMEN may have additional
properties in its unique C terminus that allow for an
autonomous activator effect on NF-kB and JNK.
Through activation of NF-kB, v-CARMEN may regulate
the expression of the cellular and viral genes important
for viral replication.
The ability to undergo apoptosis is an inherent property of all
somatic cells. Apoptosis can be triggered by a variety of stimuli,
such as ligands of the tumor necrosis factor family, cytotoxic
drugs, growth factor starvation, and infectious agents such as
viruses. Viruses are faced with the need to productively repli-
cate within a receptive intracellular environment and thus
have evolved strategies to counteract the death signaling ma-
chinery (1, 2). Documented viral apoptosis inhibitors include
proteins that have a bcl-2-like function or those that directly
interfere with caspase activity. We and others (3–5) have re-
cently characterized a family of viral gene products, collectively
called v-FLIPs,1 that are produced by many g-herpesviruses
and by the molluscum contagiosum virus. The striking struc-
tural feature of the viral FLIPs is the presence of a tandem
repeat of a so-called death effector domain (DED). The DED
has structural homology to a motif called the death domain,
which is present in the cytoplasmic part of death receptors such
as Fas. The death domain of Fas interacts with the C-terminal
death domain of FADD, which in turn induces the binding of
the N-terminal DED of FADD to the DED-containing prodo-
main of caspase-8. The recruitment and activation of caspase-8
by Fas result in the processing of downstream caspases and the
induction of apoptosis (6). The DED-containing v-FLIPs inter-
fere with the FADD-caspase-8 interaction and hence block apo-
ptosis (3). Thus, the DED and the death domain are important
protein-protein interaction modules implicated in cell death
signaling.
Recently, the existence of a third related protein-protein
interaction domain, designated the caspase-recruiting domain
(CARD), was revealed (7). The prototype CARD is found in
Apaf-1, a mitochondrial protein related to the Caenorhabditis
elegans protein CED-4 (8). Activation of Apaf-1 by cytochrome
c leads to the recruitment of the CARD-containing caspase-9
and to subsequent apoptosis (9). Additional CARD-dependent
protein interactions have been identified. The CARD-contain-
ing adaptor molecule RAIDD recruits caspase-2 to the tumor
necrosis factor receptor 1 (10), whereas the CARD-containing
kinase CARDIAK/RIP-2 may mediate both the recruitment and
activation of caspase-1 by CD40 and the activation of JNK and
NF-kB (11, 12). The respective recruiting/regulatory proteins of
other CARD-containing caspases (caspase-4, -5, -11, and -12),
are currently not known. Other CARD-containing proteins, i.e.
ARC (13), c-IAP1, and c-IAP2 (14), are involved in the regula-
tion of apoptosis.
We have previously reported on a gene product from equine
herpesvirus type 2 (EHV-2), designated E10, that comprises a
CARD motif (7). Because the E8 gene, which is found in the
same region of the EHV-2 genome, encodes the potent apopto-
sis inhibitor v-FLIP, we undertook a study to investigate
whether E10 may also be implicated in the modulation of
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EXPERIMENTAL PROCEDURES
Cloning of Viral, Human, and Mouse CARMEN cDNA—The com-
plete ORF of viral E10 was amplified from viral EHV-2 DNA (a kind gift
of A. J. Davison, Glasgow, United Kingdom). The amplified E10 ORF is
longer than the originally published E10 ORF (after resequencing of the
respective region of the viral genome, we had to correct the originally
reported E10 sequence (15) that predicted a shorter ORF). EST clones
encoding a related human and mouse CARD-containing protein were
identified in the dbEST data base at the National Center for Biotech-
nology Information (EST clones 703916 and 574273) by performing a
data base search using a generalized profile method (16) based on the
sequence homology among other CARD-containing proteins (7).
Northern Blot Analysis—Northern blot analysis was performed by
probing a murine multiple tissue Northern blot (CLONTECH), accord-
ing to the manufacturer’s instructions, with a 32P-labeled antisense
RNA probe encompassing the complete ORF of murine CARMEN
cDNA.
Expression Vectors—cDNAs encoding CARMEN proteins or frag-
ments thereof were amplified by standard polymerase chain reaction
methods using Pwo polymerase (Boehringer Mannheim) and specific
primers containing suitable restriction sites on the 59- and 39-end on
cDNA templates from the following sources. Full-length human CAR-
MEN (amino acids 2–233), a deletion construct encompassing the N-
terminal CARD (amino acids 2–89, h-CARMEN-NT) or lacking the
CARD (amino acids 85–233, h-CARMEN-CT), was amplified on EST
clone 703916; full-length murine CARMEN (amino acids 2–233) was
amplified on EST clone 574273; and full-length v-CARMEN was ampli-
fied on EHV-2 DNA. An internal BamHI site at nucleotide 412 of
v-CARMEN was used for the construction of a C-terminally truncated
v-CARMEN encompassing the N-terminal CARD (amino acids 1–139,
v-CARMEN-NT). A deletion construct lacking the CARD (amino acids
109–311, v-CARMEN-CT) was amplified on cloned full-length v-CAR-
MEN. Amplified products were cloned into pCRblunt (Invitrogen) and
sequenced. Subcloning into expression vectors derived from pCR-3 (In-
vitrogen) yielded expression constructs with an N-terminal FLAG, he-
magglutinin (HA), or vesicular stomatitis virus (VSV) tag. For the yeast
two-hybrid interaction assay, sequenced constructs of v-CARMEN, h-
CARMEN, and their above described N-terminally truncated versions
were subcloned into pGBT-9 or pGAD10 (CLONTECH), yielding GAL4-
DNA-binding proteins or GAL4-activation-domain fusion proteins,
respectively.
The following expression plasmids were obtained from the indicated
sources: NF-kBLuc (V. Jongeneel, Lausanne, Switzerland); FLAG-
tagged JNK (C. Widmann, Denver, CO); HA-tagged p38 (J. S. Gutkind,
NIDR, Bethesda, MD); ERK-1 (J. Pouysse´gur, Nice, France); dominant
negative (DN) GFP-TRAF2 (amino acids 266–501) (H. Wajant, Stuttgart,
Germany); DN TRAF6, wild type, and DN IKK2 (S. Whiteside and A.
Israe¨l, Paris, France); v-19 ras (E. Reichmann, Lausanne, Switzerland).
Transfection, Immunoprecipitation, Mitogen-activated Protein Ki-
nase, and NF-kB Activation Assays—These techniques were performed
essentially as described before (11, 17, 18). Activation of p38 and ERK-1
was detected using phosphospecific antibodies that detect the active
form of the respective mitogen-activated protein kinases (New England
Biolabs).
Two-hybrid Interaction Assay—Protein-protein interactions were an-
alyzed by cotransforming a plasmid encoding a v-CARMEN-GAL4-
DNA-binding (GAL4-DB) fusion protein with plasmids encoding vari-
ous v/h-CARMEN-GAL4-activation-domain fusion protein constructs
(2.5 mg of each plasmid) into the Saccharomyces cerevisiae strain Y190
and subsequent filter lift assays for colony color development according
to the manufacturer’s instructions (CLONTECH, yeast protocols hand-
book). Controls were performed by using the respective vectors without
insert.
RESULTS AND DISCUSSION
To study the possible physiological role of the viral E10 gene
product, designated v-CARMEN (for CARD-containing mole-
cule enhancing NF-kB, see below), we assessed effector func-
tions that have been described for other CARD-containing pro-
teins such as modulation of apoptosis and activation of JNK
and NF-kB. Expression constructs encoding v-CARMEN and a
number of proapoptotic proteins were transfected into 293T
cells, and the presence of apoptotic cells was subsequently
analyzed. Although overexpression of v-CARMEN was very
weakly cytotoxic, expression of Fas, DR-3/TRAMP, TRAIL-R1,
or TRAIL-R2 lead to extensive cell death, which was neither
inhibited nor enhanced by the coexpression of v-CARMEN
(data not shown). Stable transfection of Jurkat cells with v-
CARMEN or a construct lacking the CARD motif did not alter
the cells’ susceptibility to Fas or staurosporine-induced apo-
ptosis (data not shown).
Next we tested whether v-CARMEN was able to stimulate
activation of JNK by coexpressing v-CARMEN with JNK in
293T cells. Activation of JNK leads to its phosphorylation by
upstream kinases, which can be detected by antibodies specif-
ically recognizing the phosphorylated but not the unphospho-
rylated form of JNK. Compared with the vector control, v-
CARMEN potently induced JNK activation (Fig. 1A).
Activation of the kinase appeared to be dependent on the
CARD motif, because overexpression of the C-terminal part of
v-CARMEN (lacking the CARD) did not result in increased
JNK activation, whereas a C-terminally truncated construct
encompassing the CARD (v-CARMEN-NT) was able to induce
some JNK activation. v-CARMEN-induced JNK activation was
not inhibited by dominant negative versions of TRAF2 or apo-
ptosis signal-regulating kinase 1 (ASK 1) (data not shown),
indicating that v-CARMEN acts downstream or independently
of these mediators of tumor necrosis factor-induced JNK acti-
vation (19). v-CARMEN also activated the stress kinase p38 in
a CARD-dependent manner (Fig. 1B). In contrast, no activation
of the MAP kinase ERK-1 was seen by the overexpression of the
viral protein (Fig. 1C).
The ability of v-CARMEN to activate an NF-kB luciferase
reporter plasmid was next investigated. Expression of v-CAR-
MEN in 293T cells resulted in a dose-dependent activation of
the reporter gene, reaching an approximately 10-fold increase
in luciferase activity as compared with the vector control (Fig.
1, D and E). Induction of NF-kB activity by v-CARMEN was
almost as strong as that seen with the adaptor protein MyD88
(Fig. 1D), which links interleukin-1R and toll receptors to
NF-kB signaling pathways (17, 20–22). Similar to the require-
ment for JNK activation, the initiation of NF-kB signals by
v-CARMEN was dependent on the presence of the CARD motif.
Activation of NF-kB is dependent on the formation of a
multiprotein complex, which is comprised of TRAFs, the NF-
kB-inducing kinase (NIK), IKK1, IKK2, the NF-kB essential
modulator (NEMO), IkBa, IkBb, and the IKK-complex-associ-
ated protein (ICAP) (23). Dominant negative versions of some
of these proteins can block NF-kB-activating signals triggered
by upstream receptors. Indeed, DN IKK2, but not DN TRAF2
or DN TRAF6, inhibited v-CARMEN-mediated NF-kB activa-
tion, indicating that the overexpression of the viral protein
initiated a signal cascade downstream of TRAFs but upstream
of IKK2 in the NF-kB signaling complex (Fig. 1F and data not
shown).
CARDs are known to serve as protein-protein interaction
motifs (9, 10). It was therefore likely that v-CARMEN exerted
its JNK and NF-kB activating effects through association with
another CARD-containing protein. In this regard, by screening
public data bases with a CARD sequence profile (7, 16) we
discovered the presence of a novel CARD protein with high
homology to the CARD motif of v-CARMEN, which we call
c-CARMEN (Fig. 2A). v-CARMEN corresponds to a 311-amino
acid protein with an N-terminal CARD motif followed by a
C-terminal, glycine-rich extension of approximately 200 amino
acid residues. After the resequencing of this region of the viral
genome, we had to correct the original E10 sequence deposited
in the data base, which predicted a shorter ORF corresponding
to only 210 amino acids (15). The predicted protein size of the
corrected 311-amino acid v-CARMEN (34 kDa) agrees well
with the 36-kDa protein detectable after expression in 293T
cells (see Fig. 1). c-CARMEN (the cellular homologue of v-
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CARMEN) consists of an N-terminal CARD followed by a C-
terminal extension of approximately 130 amino acids with a
predicted molecular size of 26 kDa. The CARD of v-CARMEN
shows 47 and 46% sequence identity with mouse and human
c-CARMEN, respectively, but only approximately 20–25% se-
quence identity with other CARD-containing proteins (Fig. 2B).
Little sequence identity is found in the C-terminal extensions
of the viral and the cellular CARMEN, the latter of which lacks
the glycine-rich regions. Neither of the C-terminal extensions
has significant homology to protein sequences currently found
in public data bases.
Northern blot analysis revealed that murine CARMEN (m-
CARMEN) was expressed in all mouse tissues as a single
transcript of approximately 2.4 kilobases (Fig. 3), suggesting
that the protein is of functional relevance in many cell types.
The potential interaction of c-CARMEN with other CARD-
containing proteins was examined by coexpression of the dif-
ferent FLAG-tagged CARD proteins with HA-tagged human
FIG. 1. Activation of JNK, p38, and NF-kB by v-CARMEN. Panels A and B, 293T cells (2 3 105) were transfected with 3 mg of a JNK or a
p38 expression construct in combination with plasmids encoding full-length v-CARMEN, its C-terminal portion lacking the CARD (v-CARMEN-
CT, amino acids 109–311), or the N-terminal CARD alone (v-CARMEN-NT, amino acids 1–139). 24 h after transfection, JNK or p38 activation was
determined by Western blotting using antibodies specifically detecting the active phosphorylated kinases. The expression levels of the various
FLAG-tagged v-CARMEN constructs, FLAG-tagged JNK, and HA-tagged p38 were determined using anti-FLAG and anti-HA antibodies,
respectively. Panel C, analogous experiments were done with ERK-1 by using an HA-tagged ERK-1 construct. Overexpression of active Ras (v-19)
was used as a positive control for ERK-1 activation. Panels D and E, 293T cells were cotransfected with 1 mg of an NF-kB luciferase reporter
plasmid (pNF-kBLuc), 0.5 mg of b-galactosidase expression vector (pCMV b-gal), the indicated v-CARMEN constructs, and an empty vector to give
5.5 mg of total DNA. Luciferase activities were determined 24 h after transfection and normalized on the basis of b-galactosidase values as
described previously (17). Values shown are averages for representative experiments in which each transfection was carried out in duplicate. Panel
F, inhibition of v-CARMEN-induced NF-kB activation by DN IKK2. 293T cells were cotransfected with 1 mg of pNF-kBLuc, 0.5 mg of pCMV b-gal,
1.5 mg of v-CARMEN expression vector and/or the indicated IKK2 expression vectors, and an empty vector to give 6 mg of total DNA. Samples were
analyzed for luciferase activity as in panel D.
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CARMEN (h-CARMEN) in 293T cells followed by co-immuno-
precipitation studies. Using this technique, an interaction was
noted only between v-CARMEN and h-CARMEN, whereas
caspase-1, -2, -4, and -9, RAIDD, or CARDIAK did not interact
with h-CARMEN (Fig. 4A). We also did not detect an interac-
tion with the CARD motif of Apaf-1, cIAP-1, or cIAP-2 (data not
shown). A truncated version of v-CARMEN lacking the CARD
motif (v-CARMEN-CT) did not interact with either human or
mouse c-CARMEN, indicating that binding was mediated
through the CARD motif (Fig. 4B). An analysis of this interac-
tion in the yeast two-hybrid system confirmed a direct and
CARD-dependent interaction of v-CARMEN with h-CARMEN
(Table I). Interestingly, c-CARMEN of human and mouse ori-
gin also formed CARD-dependent homodimers in 293T cells
(Fig. 4B). We were unable to detect homodimers of v-CARMEN
in 293T cells, although a homodimeric interaction of v-CAR-
MEN was detected in the yeast two-hybrid system (Table I).
Interestingly, the interaction between v-CARMEN and its cel-
lular homologue lead to an altered electrophoretic mobility of
the c-CARMENs (Fig. 4B). Human and murine CARMEN mi-
grated slightly slower by SDS-polyacrylamide gel electrophore-
sis in the presence of v-CARMEN, suggesting that the cellular
homologue may undergo a post-translational modification such
as phosphorylation upon interaction with the viral homologue.
Whether this is because of the JNK/IKK kinase-inducing ac-
tivity of v-CARMEN (potentially recruiting kinases to the com-
plex of viral/cellular CARMEN) remains to be seen.
Because v-CARMEN was a potent activator of the JNK and
NF-kB signaling pathways, we anticipated a similar function
for the cellular homologue. However, overexpression of either
full-length c-CARMEN or of domains thereof was not capable of
activating these signaling pathways in 293T cells (Fig. 5, A and
B, and data not shown). c-CARMEN and its N- or C-terminal
deletion constructs also did not inhibit NF-kB or JNK signals
induced by v-CARMEN or by triggering the receptors for tumor
necrosis factor or interleukin-1 (data not shown), indicating
that the cellular homologue is not essential to these pathways.
FIG. 2. Panel A, structure and predicted amino acid sequence of viral, human, and mouse CARMEN. CARMENs contain a highly homologous
CARD motif followed by an unrelated region of approximately 130–200 amino acids. Panel B, the CARD motif of CARMENs is aligned to the
CARDs of RAIDD, caspase-1, -2, -4, -5, -9, -11, and -12, c-IAP1, c-IAP2, Apaf-1, ARC, CED-3, and CED-4 (7). For each block of aligned sequences,
black boxes indicate .50% amino acid sequence identity and gray shading indicates .50% sequence similarity through conservative amino acid
substitutions.
FIG. 3. Tissue distribution of murine CARMEN transcripts. A
Northern blot of various mouse tissues (CLONTECH) was probed with
a 32P-labeled antisense RNA fragment covering the complete murine
CARMEN-coding region, and the blots were subsequently hybridized
with a b-actin probe.
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We considered that the difference in signaling by v-CAR-
MEN versus c-CARMEN might be because of their ability to
interact with specific TRAF molecules, because members of the
TRAF family of adaptor proteins have been shown to be impli-
cated in the activation of transcription through JNK- and NF-
kB-dependent pathways (reviewed in Ref. 24). We therefore
tested the ability of c-CARMEN and v-CARMEN to bind to
specific members of the TRAF family by coexpression of the
respective proteins in 293T cells. The result of the co-precipi-
tation study shown in Fig. 5 revealed a clear difference in the
TRAF binding specificity of c-CARMEN and v-CARMEN; hu-
man CARMEN bound specifically to TRAF1 and TRAF5,
whereas the v-CARMEN had a clear binding preference for
TRAF6 and, to a smaller degree, for TRAF3 (Fig. 5, C and D).
EHV-2 is a slow growing, cytopathogenic g-herpesvirus,
which appears to be ubiquitous in the equine population (15).
However, its precise role as a pathogen remains uncertain. In
infected horses, the virus can induce chronic pharyngitis asso-
ciated with lymphoid proliferation (25). The virus is persistent
in peripheral blood lymphocytes, suggesting that it copes well
with apoptotic processes occurring in the host. We have previ-
ously identified its DED-containing E8 gene product (v-FLIP)
as a potent inhibitor of the death receptor-signaling pathways
(3). Moreover, EHV-2 also has a predicted bcl-2 gene homo-
FIG. 4. Interaction of viral and cel-
lular CARMEN. Panel A, 293T cells
were cotransfected with an expression
vector for HA-tagged h-CARMEN and
for FLAG-tagged caspase-1, caspase-2
(Ich1S), caspase-4, caspase-9, RAIDD, and
v-CARMEN, as indicated, and anti-FLAG
immunoprecipitates were analyzed for
the presence of h-CARMEN by Western
blotting using anti-HA antibody. The
expression levels of the FLAG-tagged
CARD-proteins and HA-tagged h-CAR-
MEN in the cell extracts are shown. Panel
B, 293T cells were cotransfected with an
expression vector for HA-tagged human
or mouse CARMEN and for FLAG-tagged
v-CARMEN, c-CARMEN, and CARD-
deletion mutants thereof. Anti-FLAG im-
munoprecipitates were analyzed for the
presence of c-CARMEN as described in A.
IPs, immunoprecipitates.
TABLE I
CARD-dependent interaction of v- and h-CARMEN in the yeast two-hybrid system
Viral and human CARMEN or C-terminal (CT) constructs thereof lacking the CARD were expressed in yeast as GAL4 DNA binding (DB) or
GAL4 activation domain (AD) fusion proteins and were tested for interaction by a filter lift b-galactosidase color assay. (11) indicates blue color




h-CARMEN h-CARMEN-CT v-CARMEN v-CARMEN-CT Control
v-CARMEN 11 2 11 2 2
Control 2 2 2 2 2
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logue in its genome (2). Although its biological activity has not
yet been verified, it is predicted that the gene product of this
viral bcl-2 homologue inhibits apoptotic signals originating
from the Apaf-1/caspase-9 pathway. In this report we have
characterized the EHV-2 protein E10, designated v-CARMEN,
as a potent inducer of the NF-kB and JNK pathways. Cellular
gene products induced by the NF-kB transcription factor are
known to inhibit apoptosis by a variety of means (26, 27). Thus,
in addition to the E8-FLIP and the bcl-2 homologue, the E10/
CARMEN gene product of EHV-2 may provide the virus with a
third anti-apoptotic mechanism. In addition, NF-kB induction
by v-CARMEN may serve to control the expression of viral
genes with an NF-kB promotor in the course of viral replication
(28).
We have identified a cellular homologue and binding partner
of v-CARMEN as c-CARMEN, which is highly homologous to
the viral protein in its N-terminal CARD motif. v-CARMEN
and c-CARMEN interact directly in a CARD-dependent man-
ner yet reveal different binding specificities toward members of
the TRAF family. When overexpressed in 293T cells, v-CAR-
MEN is a potent inducer of the JNK, p38, and NF-kB tran-
scriptional pathways, whereas c-CARMEN or truncated ver-
sions thereof do not appear to activate these pathways by
themselves nor do they affect the JNK and NF-kB activating
potential of v-CARMEN. c-CARMEN may therefore act up-
stream of v-CARMEN in an as yet unidentified NF-kB/JNK-
activating pathway. Alternatively, c-CARMEN may interfere
with NF-kB/JNK activation only upon a post-translational reg-
ulatory event, such as phosphorylation, or upon interaction
with a third component lacking in our cellular system. Finally,
we cannot exclude the possibility that c-CARMEN mediates yet
another NF-kB/JNK-unrelated function of v-CARMEN and
that the observed CARD-dependent NF-kB/JNK activation
through v-CARMEN is mediated by an as yet unidentified
CARD-containing protein. Interestingly, mutation of a novel
gene (Bcl10) identical to c-CARMEN was recently reported to
be associated with B-cell lymphomas of mucosa-associated
lymphoid tissue and other tumor types (29). Further study of
the molecular mechanism of v-CARMEN function may help in
the understanding of the physiological role of its cellular ho-
mologue and its potential implication in tumor development.
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